<DOC>
	<DOCNO>NCT02953015</DOCNO>
	<brief_summary>Chronic migraine ( CM ) disable disorder grave socioeconomic consequence . Pharmacological approach affect mechanisms pain production , rehabilitation Transcutaneous Electrical Nerve Stimulation Manual Therapy may reduce neuromuscular contribute factor . The main aim study evaluate effect cervical thoracic manipulative technique combine OnabotulinumtoxinA prophylaxis headache frequency patient Chronic Migraine ( CM ) . The second aim evaluate training effect intensity headache attack , analgesic consumption , cervical range motion , TrPs sensitivity disability . The hypothesis manipulative treatment would alleviate CM symptom , turn , decrease analgesic consumption .</brief_summary>
	<brief_title>Non-pharmacological Management Chronic Migraine</brief_title>
	<detailed_description>The present study single-blind randomize control trial conduct accord Declaration Helsinki , guideline Good Clinical Practice , Consolidated Standards reporting Trials ( CONSORT ) Statement guideline . The examiner blind group assignment . If eligible , patient allocate experimental group ( EG ) control group ( CG ) use automate randomization system ( Allocation ratio 1:1 ) . The group allocation keep concealed mean seal numbered envelope . The randomization list lock desk drawer accessible main investigator . All treatment assessment perform Neurorehabilitation Unit Azienda Ospedaliera Universitaria Integrata Verona ( Italy ) . Patients ask complete daily headache diary , routinely administer patient CM admit Unit OnabotulinumtoxinA prophylaxis . In context study , daily headache diary 1 month pre-treatment ( T0 ) , treatment ( treatment phase ) 1 month post-treatment ( T1 ) consider . Moreover , T0 questionnaire concern clinical demographic data well habit like consumption coffee alcohol , smoking administer . According nature study feasibility efficacy outcome define . Feasibility outcomes patient ' compliance treatment , adverse event ( i.e . pain , discomfort ) occur treatment , number training session perform . Primary secondary outcome measure categorize efficacy outcome .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Inclusion criterion : age 18 65 year ; diagnosis CM accord fhe International Classification Headache CriteriaIII ; ineffective assumption least 3 different drug class recommend international guideline migraine treatment ; intolerance to/inefficacy primary prophylaxis therapy ; prophylactic treatment OnabotulinumtoxinA accord Phase III Research Evaluating Migraine Prophylaxis Therapy ( PREEMPT ) protocol ; least two consecutive OnabotulinumtoxinA injection . Exclusion criterion : contraindication onaBoNTA injection ; presence neurologic disorder cause/sustain migraine ; onaBoNTA treatment purpose study ; nonpharmacological treatment migraine ( e.g . massage , acupuncture ) ; severe unstable cardiovascular cerebrovascular disease ; presence infection , psychiatric disease functional disorder head structure ; severe osteoporosis ; vertebral arm fracture ; alcohol/drug abuse ; relevant medical therapy change trial ; incomplete headache diary miss information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Migraine</keyword>
	<keyword>Manipulative treatment</keyword>
	<keyword>Transcutaneous Electrical Nerve Stimulation</keyword>
</DOC>